Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 10:8:2204.
doi: 10.3389/fmicb.2017.02204. eCollection 2017.

Reporter-Based Assays for High-Throughput Drug Screening against Mycobacterium abscessus

Affiliations

Reporter-Based Assays for High-Throughput Drug Screening against Mycobacterium abscessus

Rashmi Gupta et al. Front Microbiol. .

Abstract

Mycobacterium abscessus is a non-tuberculous mycobacterium that causes pulmonary and non-pulmonary infections. M. abscessus is resistant to many chemotherapeutic agents and the current treatment options show poor clinical outcomes. Thus, there is a dire need to find new antimicrobials effective at killing M. abscessus. Screening drug libraries to identify potential antimicrobials has been impeded by the lack of validated HTS assays for M. abscessus. In this study, we developed two 384-well high-throughput screening assays using fluorescent and bioluminescent reporter strains of M. abscessus for drug discovery. Optimization of inoculum size, incubation time and the volume-per-well based on Z-factor and signal intensity yielded two complementary, robust tools for M. abscessus drug discovery with Z-factor > 0.8. The MIC of known drugs, amikacin and clarithromycin, as determined by bioluminescence was in agreement with the published MIC values. A proof-of-concept screen of 2,093 natural product-inspired compounds was conducted using the 384-well bioluminescent assay to identify novel scaffolds active against M. abscessus. Five active "hit" compounds identified in this pilot screen were confirmed and characterized by a CFU assay and MIC determination. Overall, we developed and validated a 384-well screen that offers simple, sensitive and fast screening of compounds for activity against this emerging pathogen. To our knowledge, this is the first reporter-based high-throughput screening study aimed at M. abscessus drug discovery.

Keywords: drug discovery and development; drug discovery screening; fluorescence; luminescence; non-tuberculous mycobacteria; reporter genes.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Reporter plasmids stability. Bacterial growth in CFU/ml with M. abscessus 390S-Lux (black) and 390S-mCh (gray) reporter strains with selection (S, solid circle) and no selection (NS, open circle) of the antibiotic KAN. The data is an average of three independent experiments and standard deviation is represented by error bars.
FIGURE 2
FIGURE 2
Optimization of HTS parameters. Heat map of Z-factor values from optimization of fluorescent mCherry and the bioluminescent Lux reporter screen with the M. abscessus 390S strain. The data is an average of three independent experiments.
FIGURE 3
FIGURE 3
Kinetics of reporter signal output. Fluorescent (FL) and bioluminescence (Lux) signal with and without the drug AMK with M. abscessus 390S-mCh and 390S-lux strain. The data is an average of three independent experiments and standard deviation is represented by error bars.
FIGURE 4
FIGURE 4
Discovery of hit compounds. A scatter plot showing percent inhibition of the hit compounds (49) identified from the Asinex library at 24, 48, and 72 h.
FIGURE 5
FIGURE 5
Structures of five validated hits.

References

    1. Abraham E. (2007). ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175 744–745. 10.1164/ajrccm.175.7.744b - DOI - PubMed
    1. Andreu N., Fletcher T., Krishnan N., Wiles S., Robertson B. D. (2012). Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence. J. Antimicrob. Chemother. 67 404–414. 10.1093/jac/dkr472 - DOI - PMC - PubMed
    1. Andreu N., Zelmer A., Fletcher T., Elkington P. T., Ward T. H., Ripoll J., et al. (2010). Optimisation of bioluminescent reporters for use with mycobacteria. PLOS ONE 5:e10777. 10.1371/journal.pone.0010777 - DOI - PMC - PubMed
    1. Arain T. M., Resconi A. E., Hickey M. J., Stover C. K. (1996). Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. Antimicrob. Agents Chemother. 40 1536–1541. - PMC - PubMed
    1. Ballell L., Bates R. H., Young R. J., Alvarez-Gomez D., Alvarez-Ruiz E., Barroso V., et al. (2013). Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. Chemmedchem 8 313–321. 10.1002/cmdc.201200428 - DOI - PMC - PubMed

LinkOut - more resources